Does TECLISTAMAB Cause Second primary malignancy? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with TECLISTAMAB (TECVAYLI). This represents 0.4% of all adverse event reports for TECLISTAMAB.
5
Reports of Second primary malignancy with TECLISTAMAB
0.4%
of all TECLISTAMAB reports
2
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From TECLISTAMAB?
Of the 5 reports, 2 (40.0%) resulted in death, 2 (40.0%) required hospitalization, and 3 (60.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TECLISTAMAB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TECLISTAMAB Cause?
Cytokine release syndrome (257)
Pneumonia (101)
Plasma cell myeloma (100)
Immune effector cell-associated neurotoxicity syndrome (99)
Pyrexia (86)
Covid-19 (82)
Infection (58)
Drug ineffective (52)
Neutropenia (48)
Sepsis (48)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TECLISTAMAB Alternatives Have Lower Second primary malignancy Risk?
TECLISTAMAB vs TECLISTAMAB-CQYV
TECLISTAMAB vs TEDIZOLID
TECLISTAMAB vs TEDUGLUTIDE
TECLISTAMAB vs TEDUGLUTIDE\WATER
TECLISTAMAB vs TEGAFUR